Victrelis 200mg capsule

EUEMA:by INNUSFDA:Boceprevir J05AP03(WHO) US:℞-only (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide 394730-60-0Y 10324367 7876 DB08873Y 8499830Y 89BT58KELH D08876Y ChEMBL218394Y 398493 DTXSID30960103 Interactive image O=C(N3[C@H](C(=O)NC(C(=O)C(=O)N)CC1CCC1)[C@H]2C‍‍‍‍‍‍​​​‍​​​​​​(C)([C@H]2C3)C)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1YKey:LHHCSNFAOIFYRV-DOVBMPENSA-NY Boceprevir(INN, trade nameVictrelis) is aprotease inhibitorused to treat hepatitis caused byhepatitis C virus(HCV) genotype 1.It binds to the HCVnonstructural protein 3active site. It was initially developed bySchering-Plough,then byMerckafter it acquired Schering in 2009. It was approved by theFDAin May 2011.In January 2015, Merck announced that they would be voluntarily withdrawing Victrelis from the market due to the overwhelming superiority of newer direct-acting antiviral agents, such asledipasvir/sofosbuvir.